基本信息:
- 专利标题： Anticoagulant fusion protein anchored to cell membrane
- 专利标题（中）：Zum Zellmembran verankertes Antikoagulant-Fusionprotein
- 申请号：EP05077712.7 申请日：1998-03-26
- 公开(公告)号：EP1676920A2 公开(公告)日：2006-07-05
- 发明人： Riesbeck, Kristian , Dorling, Anthony , George, Andrew John Timothy , Lechler, Robert Jan
- 申请人： IMPERIAL COLLEGE INNOVATIONS LIMITED
- 申请人地址： Level 12 Electrical and Electronic Engineering Building Imperial College London SW7 2AZ GB
- 专利权人： IMPERIAL COLLEGE INNOVATIONS LIMITED
- 当前专利权人： IMPERIAL COLLEGE INNOVATIONS LIMITED
- 当前专利权人地址： Level 12 Electrical and Electronic Engineering Building Imperial College London SW7 2AZ GB
- 代理机构： Carpmaels & Ransford
- 优先权： GB9706327 19970326; GB9720248 19970923
- 主分类号： C12N15/62
- IPC分类号： C12N15/62 ; A01K67/027 ; C12N15/00 ; C07K14/705 ; C07K14/815 ; C07K14/81 ; C12N9/64 ; C12N5/10
摘要：
The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection.
The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor.
These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell-surface is regulated according to cell-activation, for instance by targeting the protein to a suitable secretory granule.
Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (eg. after xenotransplantation).
摘要（中）：
The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor.
These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell-surface is regulated according to cell-activation, for instance by targeting the protein to a suitable secretory granule.
Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (eg. after xenotransplantation).
本发明涉及抑制血液凝固，特别是在器官排斥期间，特别是对延迟血管排斥的抑制。 本发明提供锚定于细胞膜的抗凝血蛋白。 抗凝血功能优选由肝素，抗凝血酶，水蛭素，TFPI，蜱抗凝血肽或蛇毒因子提供。 优选地防止这些抗凝血蛋白在细胞表面组成型表达。 特别地，细胞表面的表达根据细胞活化来调节，例如通过将蛋白质靶向合适的分泌颗粒。 这些蛋白质的表达使得细胞，组织和器官在移植后不易被排斥（例如在异种移植后）。
公开/授权文献:
- EP1676920B1 Anticoagulant fusion protein anchored to cell membrane 公开/授权日：2014-07-09